A revolutionary gene therapy has demonstrated remarkable potential in slowing the devastating progression of Huntington's disease. In a preliminary trial conducted by University College London (UCL), the experimental treatment, AMT-130, achieved a 75% reduction in disease progression over three years in patients receiving a high dose, compared to those receiving standard care. This breakthrough offers a beacon of hope for the 100,000 Americans affected by this inherited neurodegenerative disorder.
Huntington's disease, caused by a faulty gene that leads to the accumulation of toxic proteins damaging brain cells, typically manifests in mid-adulthood, gradually impacting movement, memory, and mood over 15-20 years. The current treatment options only manage symptoms, leaving patients with a relentlessly declining quality of life. The impact of AMT-130, however, is transformative.
This innovative therapy utilizes a harmless virus as a vector to deliver corrective genetic instructions directly to the brain. These instructions effectively silence the production of the harmful protein, addressing the root cause of the disease. Professor Ed Wild of UCL highlights the profound impact, stating that some patients have even been able to return to work. The success of the therapy was assessed through brain scans and analysis of spinal fluid, revealing a significant reduction in markers of brain cell damage.
While the results are overwhelmingly positive, the study, involving 29 patients (12 receiving the high dose), is considered preliminary. Larger-scale trials are necessary before seeking FDA approval, anticipated no sooner than 2026. The treatment's delivery requires complex brain surgery; however, patients reported manageable side effects.
Professor Sarah Tabrizi, lead scientific advisor for the trial, expresses immense enthusiasm, emphasizing the potential for AMT-130 to significantly improve patients' daily lives and preserve their functional abilities for longer. The findings, while not yet peer-reviewed, will be presented at a major medical conference soon. This groundbreaking research signifies a pivotal step toward providing a life-altering treatment for Huntington's disease, moving beyond symptom management to directly combat the disease's progression.
---
Originally published at: https://abcnews.go.com/Health/preliminary-promising-gene-therapy-shows-75-reduction-huntingtons/story?id=125904128
